Oral administration of a 2-aminopyrimidine robenidine analogue (NCL195) significantly reduces Staphylococcus aureus infection and reduces Escherichia coli infection in combination with sub-inhibitory colistin concentrations in a bioluminescent mouse model

- Nguyen, Hang Thi, Venter, Henrietta, Woolford, Lucy, Young, Kelly A., Mccluskey, Adam, Garg, Sanjay, Sapula, Sylvia S., Page, Stephen W., Ogunniyi, Abiodun David, Trott, Darren J.

Impact of a Novel Anticoccidial Analogue on Systemic Staphylococcus aureus Infection in a Bioluminescent Mouse Model

- Nguyen, Hang Thi, Venter, Henrietta, Woolford, Lucy, Young, Kelly, McCluskey, Adam, Garg, Sanjay, Page, Stephen W., Trott, Darren J., Ogunniyi, Abiodun D.

In vitro activity of robenidine analog NCL195 in combination with outer membrane permeabilizers against gram-negative bacterial pathogens and impact on systemic gram-positive bacterial infection in mice

- Pi, Hongfei, Nguyen, Hang Thi, Venter, Henrietta, Boileau, Alexandra R., Woolford, Lucy, Garg, Sanjay, Page, Stephen W., Russell, Cecilia C., Baker, Jennifer R., McCluskey, Adam, O'Donovan, Lisa A., Trott, Darren J., Ogunniyi, Abiodun D.

In vitro antimicrobial activity of Robenidine, Ethylenediaminetetraacetic acid and Polymyxin B Nonapeptide against important human and veterinary pathogens

- Khazandi, Manouchehr, Pi, Hongfei, Chan, Wei Yee, Ogunniyi, Abiodun David, Sim, Jowenna Xiao Feng, Venter, Henrietta, Garg, Sanjay, Page, Stephen W., Hill, Peter B., McCluskey, Adam, Trott, Darren J.

Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent

- Ogunniyi, Abiodun D., Khazandi, Manouchehr, Laven-Law, Geraldine, Totoli, Eliane G., Salgado, Hérida R., Pi, Hongfei, Coombs, Geoffrey W., Shinabarger, Dean L., Turnidge, John D., Paton, James C., McCluskey, Adam, Trott, Darren J., Stevens, Andrew J., Sims, Sarah K., Page, Stephen W., Garg, Sanjay, Venter, Henrietta, Powell, Andrew, White, Karen, Petrovski, Kiro R.